

SUPPORT FOR THE AMENDMENTS

Claims 1, 12-14, and 16 have been amended to re-insert the limitation in regard to the amount of Acesulfame K. Support for this amendment to Claims 1, 12-14, and 16 can be found in the same claims as originally issued.

No new matter is believed to be introduced by the above amendment.

REMARKS

Claims 1, 12-14, and 16 have been amended to re-insert the requirement that said Acesulfame K is present in said composition in an amount of 50 to 97% by weight based on the total amount of said N-[N-(3,3-dimethylbutyl)-L- α -aspartyl]- L-phenylalanine 1-methyl ester and said Acesulfame K. In view of the present amendments, the present application is now a narrowing reissue application.

Applicants submit that the present application is now in condition for allowance, and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Stephen G. Baxter, Ph.D.
Attorney of Record
Registration No. 32,884

Tel: (703) 413-3000
Fax: (703) 413 -2220